Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
2.740
-0.145 (-5.03%)
At close: Nov 20, 2026, 4:00 PM EST
2.730
-0.010 (-0.36%)
After-hours: Nov 20, 2026, 7:30 PM EST
Verrica Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Verrica Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $13.67. The average 1-year stock price forecast is 398.91% higher than the current stock price, while the lowest is $9.00 (+228.47%) and the highest is $20 (+629.93%).
Price Target: $13.67 (+398.91%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Verrica Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 | Buy | Reiterates | $12 | +337.96% | Nov 19, 2026 |
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Nov 13, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $3.72 → $20 | Buy | Maintains | $3.72 → $20 | +629.93% | Nov 13, 2026 |
| Lake Street | Lake Street | Buy Maintains $9 | Buy | Maintains | $9 | +228.47% | Sep 30, 2026 |
| Brookline Capital Markets | Brookline Capital Markets | Buy Upgrades $17 | Buy | Upgrades | $17 | +520.44% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
24.79M
from 35.58M
Decreased by -30.32%
Revenue Next Year
36.47M
from 24.79M
Increased by 47.12%
EPS This Year
-2.01
from -1.24
EPS Next Year
-1.37
from -2.01
EPS and Forward PE are based on non-GAAP adjusted numbers.